SLC5A2 and type 2 diabetes mellitus: In recent years, the guidelines of professional associations responsible for diabetes care have recommended personalization of T2DM therapy according to the presence of comorbidities, such as atherosclerotic cardiovascular disease, HF, or chronic kidney disease, in which the indicated molecules are from the class of glucose co-transporter-2 (SGLT2) inhibitors or glucagon-like-peptide-1 (GLP-1) receptor agonists with clinical evidence to reduce the risk of these complications [15].